Biotechnology
Health
Pharmaceutical

Arena Pharmaceuticals

$45.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-0.13%) Today
-$0.12 (-0.26%) After Hours

Why Robinhood?

You can buy or sell ARNA and other stocks, options, ETFs, and crypto commission-free!

About

Arena Pharmaceuticals, Inc. Common Stock, also called Arena Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. Read More It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.

Employees
194
Headquarters
San Diego, California
Founded
1997
Market Cap
2.27B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
757.45K
High Today
$46.59
Low Today
$45.79
Open Price
$46.00
Volume
107.81K
52 Week High
$51.63
52 Week Low
$31.97

Collections

Biotechnology
Health
Pharmaceutical
Biopharmaceutical
Technology

News

Yahoo FinanceMar 8

Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation

SAN DIEGO, March 8, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to severely active ulcerative colitis (UC), and olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB 2 ) in development for the treatment of visceral pain associated with gastr...

408
MarketBeatMar 3

Stock Price, News, & Analysis for Arena Pharmaceuticals

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangi...

45
Yahoo FinanceFeb 27

Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues

Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up. Arena Pharmaceuticals, Inc. ARNA reported earnings of $1.35 per share in the fourth quarter of 2018, which surpassed the Zacks Consensus Estimate of a loss of 76 cents. The bottom line also improved from a loss of 35 cents incurred in the year-ago period. Total revenues came in at $8.6 million, down 43.7% from the year-earlier period. However, the top line outpaced the Zacks Consensu...

317

Earnings

-$0.82
-$0.67
-$0.51
-$0.36
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.